Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that probably half the global antimicrobial R&D activity was represented by attendees in the room.
In a recent robust skin infection model with MRSA strain USA300, data demonstrate that a single daily dose of lead antibiotic compound, epidermicin NI01, is as effective at removing the infection as the current standard of care, justifying further pre-clinical development and representing an inflection point in the company valuation.
The work has been funded in part by Innovate UK as part of a Biomedical Catalyst award.
